Sign In
to Vote &
Create Storyboards.
 
Promising results from a phase II trial published in the journal Gastroenterology suggest adding the new drug danoprevir to the current standard care (peginterferon and ribavirin) for patients with hepatitis C leads to high rates of remission. The results raise hopes that Roche's new drug can improve the quality of life for patients with hepatitis C. Lead author Dr...
0
0
0


Storyboard
Print
Share this Article

Recommended

  • {TITLE}
    {PUBLISHER} - {PUBLISHED_DATE}
    {VIEWS}
  • Create Storyboard